CEO Nadav Kidron speaks with i24 News about the potential of oral insulin. Read and Watch here.
Bloomberg Radio: Nadav Kidron explains the development of an insulin pill for the treatment of Type 2 diabetes
Nadav Kidron, CEO at Oramed Pharmaceuticals, spoke to Bloomberg Business Week radio about the development of an insulin pill for the treatment of Type 2 diabetes. Listen to the segment here (begins at 13:33).
Oramed Pharmaceuticals CEO Nadav Kidron joins Yahoo Finance’s Brian Sozzi and Alexis Christoforous to discuss oral insulin on The First Trade. View here.
Oramed CEO Nadav Kidron speaks to WCBS Newsradio 880 about oral insulin and diabetes. Listen here: https://wcbs880.radio.com/media/audio-channel/conversation-about-oral-insulin
Jerusalem-based Oramed Pharmaceuticals has developed an innovative oral insulin capsule transforming injectable treatments into oral therapies. Oramed's CEO Nadav Kidron speaks to The Jerusalem Post about the company's technology .
Oramed CEO Nadav Kidron Speaks with Nathan Latka about Oramed, oral insulin and more. Listen to the full podcast: The Chinese Gave Him $50M For Orally Delivered Insulin Capsul Idea, Will It Take Off?
Despite an inexorable rise in the global population of type 2 diabetics, linked to changing lifestyle… Read the full article on www.thepharmaletter.com
This Tustin based Oral Insulin clinical trial in Orange County will test treatment for those with type 2 diabetes over the next 90 days. Read the full article on patch.com
For decades researchers have worked to find a way to orally administer insulin effectively to patients with diabetes. Now this game-changing treatment is one step closer to reality, with pharmaceutical company Oramed embarking on a final Phase 2b human clinical trial to prove the efficacy [...]
Nadav Kidron serves as Chief Executive Officer of Oramed Pharmaceuticals, which he co-founded in 2006. Their orally-taken insulin is game-changing technology that could revolutionize the way millions people with diabetes administer their medication. Read the full article on b2bnn.com